From a pathological perspective, it will be interesting to explore how Endo180 cooperates with cathepsin K in the contexts of primary and secondary bone cancers; however, it would be unlikely that a combined therapeutic approach incorporating cathepsin K inhibitors would be considered, given their withdrawal from further clinical evaluation due to their severe side‐effects 16. Here, MRC2 is linked to bone cancer.